BACKGROUND: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. METHODS: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. RESULTS: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI 571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. CONCLUSIONS: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.
BACKGROUND:Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. METHODS: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. RESULTS: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI 571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. CONCLUSIONS: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.
Authors: George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne Journal: J Natl Compr Canc Netw Date: 2005-03 Impact factor: 11.908
Authors: Moritz N Wente; Matthias H M Schwarzbach; Ulf Hinz; Christine Leowardi; Gunhild Mechtersheimer; Robert Krempien; Gerlinde Egerer; Helmut Friess; Markus W Büchler Journal: Langenbecks Arch Surg Date: 2006-11-28 Impact factor: 3.445